Related Experiment Video

Updated: Jul 9, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.6K

The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023

Toni K Choueiri1, Sumanta K Pal2, Bryan Lewis3

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

The Oncologist
|December 4, 2023
PubMed

Insights

The 5th Kidney Cancer Research Summit highlighted key kidney cancer research advances. Experts discussed tumor metabolism, immune pathways, clinical trials, and biomarkers for better treatments.

Area of Science:

  • Oncology
  • Nephrology
  • Immunology

Background:

  • The 5th Kidney Cancer Research Summit convened global experts in Boston, MA, in July 2023.
  • The conference covered diverse aspects of kidney cancer research, from basic science to clinical applications.

Purpose of the Study:

  • To summarize emerging areas in kidney cancer research discussed at the summit.
  • To provide concise updates on advancements in the field since the conference.

Main Methods:

  • Review of presentations and discussions from the 5th Kidney Cancer Research Summit.
  • Synthesis of information on tumor metabolism, immune pathways, clinical trials, immunotherapy, and biomarkers.
  • Inclusion of relevant updates occurring after the summit.

Main Results:

  • Key discussions focused on tumor metabolism and novel immune pathways in kidney cancer.
  • Advances in clinical trials and immunotherapy were presented, showing significant progress.
  • Development of biomarkers for kidney cancer diagnosis and treatment monitoring was a key theme.

Conclusions:

  • Emerging research areas in kidney cancer include metabolism, immunology, and biomarker development.
  • Progress in clinical trials and immunotherapy offers new hope for patients.
  • Continued collaboration and research are vital for advancing kidney cancer care.

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.6K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K